Stay updated with breaking news from Avenge Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mike Heffernan appointed Chairman of NMD Pharma's Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen
/PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision...
Sanofi did not see the efficacy it wanted in mid-stage tests of a cytokine therapy from its $2.5 billion acquisition of Synthorx. While the pharmaceutical giant isn’t giving up on the drug, it said it will restart the molecule in a new Phase 1/2 program, a setback that will lead to a €1.6 billion financial writedown.
/PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision...
A treatment that combines cytokine "drug factory" implants with a checkpoint inhibitor drug eradicates advanced-stage mesothelioma tumors in mice in days.